Novo Nordisk's Oral Obesity Defense: Cheaper Doses, a Fresh Pipeline Bet, and a Stock Still Searching for Its Footing
Published on 08/21/2026 at 14:32 | Redaktion boerse-global.de
The Danish pharma giant is quietly repositioning its weight-loss franchise for a more crowded marketplace. With competition intensifying in oral GLP-1 therapies and US patients increasingly gravitating toward cheaper options, Novo Nordisk has launched a Phase 3 trial to test whether lower maintenance doses of its Wegovy pill can hold their own. The OASIS 5 study, now underway with 450 adults living with obesity or overweight, aims to pin down the minimum effective dose — a move designed to improve adherence and trim side-effect profiles while responding to a pricing reality that is reshaping the company's revenue mix.
That reality was laid bare in a Wall Street Journal report indicating that self-paying US patients are preferentially choosing the lowest Wegovy pill doses, which cost roughly half as much as the 25-mg maintenance strength. It is a demand pattern that directly cuts into the economics of Novo Nordisk's most important growth product, and the company is clearly listening.
A Pipeline Built for a Post-Semaglutide World
Diversification is the watchword. Novo Nordisk has quietly advanced a previously undisclosed obesity candidate, NNC0721-8060, into a Phase 1 trial involving 142 participants, with semaglutide serving as the comparator. The move signals an effort to reduce reliance on a single mechanism of action and build out a successor generation of therapies.
That ambition was previewed in May at the European Congress on Obesity in Istanbul, where Phase 3 data from the OASIS 4 study showed "early responders" on the oral 25-mg Wegovy dose achieving a 21.6% weight reduction by week 64. Among patients with limited mobility, 77.3% recorded clinically meaningful improvements in physical function.
The pipeline push extends beyond obesity. Novo Nordisk recently launched US distribution of Awiqli, the first once-weekly basal insulin for type 2 diabetes, adding another commercial string to its bow.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analyst Skepticism and a Stock in the Doldrums
The market, however, remains unconvinced. Berenberg downgraded Novo Nordisk from Buy to Hold on August 17, trimming its price target from $50 to $47. The analysts said their prior bullish thesis — predicated on optimism around the Wegovy pill — had already played out in the first half. Now, they anticipate intensifying competition in the oral obesity segment during the second half. The downgrade followed a similar move by DZ BANK's Elmar Kraus, who had placed the stock on Hold on August 7.
The shares are feeling the weight of that skepticism. Trading at €39.47, the stock sits 28% below its 52-week high of €54.86 reached in January. Over the past 30 days, the shares have shed 6.3%, and the year-to-date decline stands at 10%. The relative strength index of 42.4 points to a weak but not oversold market posture.
The proximate cause for concern: second-quarter sales of the Wegovy pill came in at 3.22 billion Danish kroner, marginally short of the 3.27 billion kroner analysts had penciled in. Since its January launch, more than 5 million prescriptions have been written — evidence of genuine demand — but the slight miss underscores the competitive dynamics Berenberg now warns about.
Novo Nordisk itself flagged tougher US conditions in early August, citing prescription trends in injectable GLP-1s, heightened competition, and reduced Medicaid reimbursement for obesity medications as drivers of an expected revenue decline in the US market.
Legal Wins and Lingering Liabilities
On the legal front, the company secured a partial victory on August 5 when the District Court of The Hague issued a preliminary injunction against Dutch firm Ceban Ziekenhuisfarmacie B.V. The court found that Ceban's imitation semaglutide nasal spray infringed Novo Nordisk's supplementary protection certificate. Ceban must halt sales immediately, remove product references from listings and websites, disclose supply chain details, and cover Novo Nordisk's legal costs.
The counterweight to such wins is the growing mass of litigation in the US. A consolidated proceeding before a federal court in Pennsylvania now counts 3,928 pending cases alleging gastrointestinal damage linked to Ozempic and Wegovy. Eli Lilly, maker of Mounjaro, is also a defendant. While no tangible financial risk has yet crystallized, the sheer volume underscores how much the side-effect question continues to shadow the entire drug class.
Buybacks, Dividends, and the Road Ahead
Amid the operational noise, Novo Nordisk has pressed on with its share repurchase program. Between February 4 and August 14, the company bought back 28,884,179 B-shares at an average price of 279.80 Danish kroner, representing transaction volume of roughly 8.08 billion kroner. The ex-dividend date for the interim dividend fell on August 14 for A- and B-shares, and on August 17 for ADRs.
Investors now have two dates circled on the calendar: the Capital Markets Day on September 21, focused on early- and mid-stage pipeline projects, and third-quarter results due November 4. Between now and then, the central question — just how much competitive damage the oral segment will absorb — is likely to dictate the share price trajectory. Whether the broad pipeline offensive can restore lost investor confidence will depend on how quickly new study data translates into compelling evidence.
Ad
Novo Nordisk Stock: New Analysis - 21 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
